Cipla News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Cipla Ltd. authored by Axis Direct and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Axis Direct

Keep track of all breaking news and updates on Cipla from all sources in a single place.

Load latest

Cipla Ltd.

29 Jul 2025

1493.80

-0.46%

Company Update

Cipla Ltd - 500087 - Intimation Under Regulation 30 Read With Schedule III Of The SEBI …

BSE India

Please find attached disclosure on ESG rating

pdf

Cipla Ltd.

29 Jul 2025

1493.80

-0.46%

Stock to buy today: Cipla (1,571) BUY

Business Line

Cipla share price can rise to 1,650

Number of FII/FPI investors decreased from 1124 to 1085 in Sep 2025 qtr

Cipla shares rally 6% in 2 days as Q1 results impress; brokerages raise target up to Rs 1,875

Economic Times | 28 Jul 2025 2 more

Cipla Ltd.

28 Jul 2025

1493.80

-0.46%

Earnings Call

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

We are enclosing herewith a copy of the transcript of the Company''s Q1 FY26 earning conference call dated 25th July, 2025

pdf

Cipla Ltd.

28 Jul 2025

1493.80

-0.46%

Result Update:Cipla

Buy: Cipla Ltd.

Axis Direct

We remain positive on the stock with a BUY rating and arrive at a target price of Rs 1,700 per share.

Geojit BNP Paribas downgraded Cipla Ltd. to Hold with a price target of 1645.0 on 23 Dec, 2025.

Cipla Ltd.

27 Jul 2025

1493.80

-0.46%

Next US fix could stanch Cipla's Revlimid bleed amid pricing pressure

Business Standard

Generics pipeline starts to pulse as Advair, Symbicort, and Abraxane prepare to hit the vein

Geojit BNP Paribas downgraded Cipla Ltd. to Hold with a price target of 1645.0 on 23 Dec, 2025.

Cipla Ltd.

27 Jul 2025

1493.80

-0.46%

Company Update

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Please find attached newspaper advertisement

pdf

Cipla Ltd.

27 Jul 2025

1493.80

-0.46%

Cipla (CIPLA IN) Q1FY26 Result Update Strong US...

Buy: Cipla Ltd.

Prabhudas Lilladhar

CIPLA's Q1FY26 EBITDA (Rs17.8bn; 25.6% OPM) was 6% ahead of our estimates. Cipla managed to deliver strong margins during the quarter. During the quarter company witnessed price erosion for its generic products which was offset by new launches such as gAbraxane. Mgmt guided strong US revenues of $1bn for FY27 despite gRevlimid erosion. We expect Cipla to maintain its existing US sales run-rate. This will be aided by several high value niche launches in the US like gAbraxane, Nilotininb, gAdvair. Further, Cipla's...

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

26 Jul 2025

1493.80

-0.46%

US business on a strong footing

Buy: Cipla Ltd.

Target

ICICI Securities Limited

Cipla reported an in-line Q1FY26 result led by growth across the US and South Africa. Despite price erosion in gRevlimid, it posted a 156bps YoY (+133bps QoQ) surge in gross margin to 68.8%.

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

25 Jul 2025

1493.80

-0.46%

US tariffs will not have debilitating' impact on pharma industry: Cipla global MD & CEO

Business Line

Cipla's top executive Umang Vohra said that tariffs on meds pharma sector will not be as high as others, given the importance of medicines in everyone's lives.

Geojit BNP Paribas downgraded Cipla Ltd. to Hold with a price target of 1645.0 on 23 Dec, 2025.

Cipla Q1 net profit up 10%, driven by consumer health and generics

Business Standard | 25 Jul 2025 3 more

Cipla Ltd.

25 Jul 2025

1493.80

-0.46%

Earnings Call

Cipla Ltd - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Pursuant to Regulation 30 read with Part A of Schedule III and Regulation 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the earnings conference call for Q1FY26 held today is available on the Company''s website at https://www.cipla.com/audio/13917

pdf

Is Cipla Ltd. worth buying?

638 Votes:

Buy 75.86%

Sell 13.64%

Hold 10.5%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf